Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
Northwest Biotherapeutics announced that CTO Dr. Marnix Bosch will present data at the British Neuro-Oncology Society meeting showing DCVax-L survival extension using propensity score matching. The presentation focuses on the 331-patient Phase III trial for glioblastoma, for which a Marketing Authorization Application is currently under review in the UK.
Key figures
- Drug Name
- DCVax-L
- Maa Status
- under review
- Patient Count
- 331
- Phase Of Trial
- Phase III
- Presentation Title
- DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.